Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Obatoclax + Trabectedin|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Obatoclax||GX015-070||BCL2 Family Inhibitor 6||Obatoclax (GX015-070) is a pan-BCL2 family inhibitor, which leads to induction of tumor cell apoptosis (PMID: 18040043, PMID: 17332241, PMID: 32367199).|
|Trabectedin||Yondelis||ET-743||Chemotherapy - Alkylating 16||Yondelis (trabectedin) is a marine-derived alkaloid that binds to DNA and induces DNA strand breaks, leading to cell cycle arrest and cell death in tumor cells (PMID: 24755886). Yondelis (trabectedin) is FDA approved for metastatic liposarcoma or leiomyosarcoma who received prior anthracycline treatment (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|